Trial Profile

A Randomized, Double-Blind, Placebo controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chronic Kidney Disease: Evaluation of Safety and Efficacy (AMBER)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Apr 2021 Results assessing the prespecified subgroups by sex, biological differences between men and women contribute to variations in drug response, presented at the Joint Meeting of the European Society of Hypertension and International Society of Hypertension.
03 Mar 2021 According to a Vifor media release, European Medicines Agency approved important changes to the label in December which included data from the phase-II AMBER clinical study.
25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com